logo-loader
Co-Diagnostics

Co-Diagnostics shares climb after eliminating debt and unveiling stock sale

Investors are applauding the molecular diagnostics company's move to pay down all its debt via the conversion of a $2 million note to preferred shares

DNA strand
The Utah company makes technology for tests that focus on the detection and analysis of DNA and RNA

Co-Diagnostics Inc (NASDAQ:CODX) shares soared Wednesday after the molecular diagnostics company paid down its debt and announced the sale of $3 million of its preferred stock at $1.20 per share.

The transaction included the conversion of a $2 million note to preferred shares, which eliminated the company’s debt, as well as an additional sale of $1 million of preferred shares for cash.

READ: Co-Diagnostics shares soar as its technology is used in Stanford cancer study

“This financing benefits our shareholders by providing additional capital to accelerate our growth strategy,” said Dwight Egan, CEO of Co-Diagnostics, in a statement.

Based in Salt Lake City, Co-Diagnostics is a molecular diagnostics company that makes technology for tests that focus on the detection and analysis of DNA and RNA. The company also uses its proprietary technology to design specific tests to locate genetic markers.

Co-Diagnostics’ CoPrimer technology, for example, is being used by scientists at Stanford to improve their detection methods of the mutations which cause cancer. 

The shares more than doubled to $2.38 in afternoon trade on Wednesday.

Contact Ellen Kelleher at [email protected]

Quick facts: Co-Diagnostics

Price: $1.13

Market: NASDAQ
Market Cap: $19.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

1 day, 20 hours ago

2 min read